Skip to main content
Erschienen in: World Journal of Surgery 2/2020

09.09.2019 | Original Scientific Report

Anti-Thyroid Antibodies and TSH as Potential Markers of Thyroid Carcinoma and Aggressive Behavior in Patients with Indeterminate Fine-Needle Aspiration Cytology

verfasst von: Mohammadmehdi Adhami, Peter Michail, Apoorva Rao, Chhavi R. Bhatt, Simon Grodski, Jonathan W. Serpell, James C. Lee

Erschienen in: World Journal of Surgery | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Indeterminate fine-needle aspiration cytology (FNAC) imposes challenges in the management of thyroid nodules. This study aimed to examine whether preoperative anti-thyroid antibodies (Abs) and TSH are indicators of thyroid malignancy and aggressive behavior in patients with indeterminate FNAC.

Methods

This was a retrospective study of thyroidectomy patients from 2008 to 2016. We analyzed Abs and TSH levels, FNAC, and histopathology. Serum antibody levels were categorized as ‘Undetectable’, ‘In-range’ if detectable but within normal range, and ‘Elevated’ if above upper limit of normal. ‘Detectable’ levels referred to ‘In-range’ and ‘Elevated’ combined.

Results

There were 531 patients included. Of 402 patients with preoperative FNAC, 104 (25.9%) had indeterminate cytology (Bethesda III–V). Of these, 39 (37.5%) were malignant and 65 (62.5%) benign on histopathology. In the setting of indeterminate FNAC, an increased risk of malignancy was associated with ‘Elevated’ thyroglobulin antibodies (TgAb) (OR 7.25, 95% CI 1.13–77.15, P = 0.01) and ‘Elevated’ thyroid peroxidase antibodies (TPOAb) (OR 6.79, 95% CI 1.23–45.88, P = 0.008). Similarly, while still ‘In-range’, TSH ≥ 1 mIU/L was associated with an increased risk of malignancy (OR 3.23, 95% CI 1.14–9.33, P = 0.01). In all patients with malignancy, the mean tumor size was 8 mm larger in those with TSH ≥ 1 mIU/L (P = 0.03); furthermore, in PTC patients, ‘Detectable’ TgAb conferred a 4 × risk of lymph node metastasis (95% CI 1.03–13.77, P = 0.02).

Conclusion

In this cohort, in indeterminate FNAC patients, Abs and TSH were associated with an increased risk of malignancy. Additionally, TgAb and TSH were potential markers of aggressive biology. As such, they may be diagnostic and prognostic adjuncts.
Literatur
1.
Zurück zum Zitat Parsa AA, Gharib H (2018) Chapter 1, Epidemiology of thyroid nodules. In: Gharib H (ed) Thyroid nodules - diagnosis and management. Humana Press, Cham, p 7 Parsa AA, Gharib H (2018) Chapter 1, Epidemiology of thyroid nodules. In: Gharib H (ed) Thyroid nodules - diagnosis and management. Humana Press, Cham, p 7
2.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Keutgen XM, Filicori F, Fahey TJ (2013) Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev Mol Diagn 13(6):613–623PubMed Keutgen XM, Filicori F, Fahey TJ (2013) Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. Expert Rev Mol Diagn 13(6):613–623PubMed
4.
Zurück zum Zitat Cibas ES, Ali SZ (2009) The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 132(5):658–665PubMed Cibas ES, Ali SZ (2009) The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol 132(5):658–665PubMed
5.
Zurück zum Zitat Jooya A, Saliba J, Blackburn A et al (2016) The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules. J Otolaryngol Head Neck Surg 45(1):51PubMedPubMedCentral Jooya A, Saliba J, Blackburn A et al (2016) The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules. J Otolaryngol Head Neck Surg 45(1):51PubMedPubMedCentral
6.
Zurück zum Zitat Schneider DF, Cherney Stafford LM, Brys N et al (2017) Gauging the extent of thyroidectomy for indeterminate thyroid nodules: an oncologic perspective. Endocr Pract 23(4):442–450PubMedPubMedCentral Schneider DF, Cherney Stafford LM, Brys N et al (2017) Gauging the extent of thyroidectomy for indeterminate thyroid nodules: an oncologic perspective. Endocr Pract 23(4):442–450PubMedPubMedCentral
7.
Zurück zum Zitat Uhliarova B, Hajtman A (2018) Hashimoto's thyroiditis: an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol 84(6):729–735PubMed Uhliarova B, Hajtman A (2018) Hashimoto's thyroiditis: an independent risk factor for papillary carcinoma. Braz J Otorhinolaryngol 84(6):729–735PubMed
8.
Zurück zum Zitat Seifman MA, Grodski SF, Bailey M et al (2011) Surgery in the setting of Hashimoto's thyroiditis. ANZ J Surg 81(7–8):519–523PubMed Seifman MA, Grodski SF, Bailey M et al (2011) Surgery in the setting of Hashimoto's thyroiditis. ANZ J Surg 81(7–8):519–523PubMed
9.
Zurück zum Zitat Korniluk A, Koper O, Kemona H et al (2017) From inflammation to cancer. Ir J Med Sci 186(1):57–62PubMed Korniluk A, Koper O, Kemona H et al (2017) From inflammation to cancer. Ir J Med Sci 186(1):57–62PubMed
10.
Zurück zum Zitat Besler E, Citgez B, Aygun N et al (2019) The relationship of clinicopathological factors of the tumor with preoperative TSH level in papillary thyroid cancers. Eurasian J Med 51(1):8–11PubMed Besler E, Citgez B, Aygun N et al (2019) The relationship of clinicopathological factors of the tumor with preoperative TSH level in papillary thyroid cancers. Eurasian J Med 51(1):8–11PubMed
11.
Zurück zum Zitat Hu N, Li ZM, Liu JF et al (2016) An overall and dose-response meta-analysis for thyrotropin and thyroid cancer risk by histological type. Oncotarget 7(30):47750–47759PubMedPubMedCentral Hu N, Li ZM, Liu JF et al (2016) An overall and dose-response meta-analysis for thyrotropin and thyroid cancer risk by histological type. Oncotarget 7(30):47750–47759PubMedPubMedCentral
12.
Zurück zum Zitat Haymart MR, Repplinger DJ, Leverson GE et al (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93(3):809–814PubMed Haymart MR, Repplinger DJ, Leverson GE et al (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93(3):809–814PubMed
13.
Zurück zum Zitat Kim KW, Park YJ, Kim EH et al (2011) Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck 33(5):691–695PubMed Kim KW, Park YJ, Kim EH et al (2011) Elevated risk of papillary thyroid cancer in Korean patients with Hashimoto's thyroiditis. Head Neck 33(5):691–695PubMed
14.
Zurück zum Zitat Muzza M, Degl'Innocenti D, Colombo C et al (2010) The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 72(5):702–708 Muzza M, Degl'Innocenti D, Colombo C et al (2010) The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 72(5):702–708
15.
Zurück zum Zitat Hosseini S, Payne RJ, Zawawi F et al (2016) Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer? J Otolaryngol Head Neck Surg 45(1):31PubMedPubMedCentral Hosseini S, Payne RJ, Zawawi F et al (2016) Can preoperative thyroglobulin antibody levels be used as a marker for well differentiated thyroid cancer? J Otolaryngol Head Neck Surg 45(1):31PubMedPubMedCentral
16.
Zurück zum Zitat Azizi G, Keller JM, Lewis M et al (2014) Association of Hashimoto's thyroiditis with thyroid cancer. Endocr Relat Cancer 21(6):845–852PubMedPubMedCentral Azizi G, Keller JM, Lewis M et al (2014) Association of Hashimoto's thyroiditis with thyroid cancer. Endocr Relat Cancer 21(6):845–852PubMedPubMedCentral
17.
Zurück zum Zitat Repplinger D, Bargren A, Zhang YW et al (2008) Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150(1):49–52PubMed Repplinger D, Bargren A, Zhang YW et al (2008) Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 150(1):49–52PubMed
18.
Zurück zum Zitat Zhang Y, Dai J, Wu T et al (2014) The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 140(6):1021–1026PubMed Zhang Y, Dai J, Wu T et al (2014) The study of the coexistence of Hashimoto's thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 140(6):1021–1026PubMed
19.
Zurück zum Zitat Anil C, Goksel S, Gursoy A (2010) Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 20(6):601–606PubMed Anil C, Goksel S, Gursoy A (2010) Hashimoto's thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 20(6):601–606PubMed
20.
Zurück zum Zitat Matesa-Anic D, Matesa N, Dabelic N et al (2009) Coexistence of papillary carcinoma and Hashimoto's thyroiditis. Acta Clin Croat 48(1):9–12PubMed Matesa-Anic D, Matesa N, Dabelic N et al (2009) Coexistence of papillary carcinoma and Hashimoto's thyroiditis. Acta Clin Croat 48(1):9–12PubMed
21.
Zurück zum Zitat Castagna MG, Belardini V, Memmo S et al (2014) Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. J Clin Endocrinol Metab 99(9):3193–3198PubMed Castagna MG, Belardini V, Memmo S et al (2014) Nodules in autoimmune thyroiditis are associated with increased risk of thyroid cancer in surgical series but not in cytological series: evidence for selection bias. J Clin Endocrinol Metab 99(9):3193–3198PubMed
22.
Zurück zum Zitat Selek A, Cetinarslan B, Tarkun I et al (2017) Thyroid autoimmunity: is really associated with papillary thyroid carcinoma? Eur Arch Otorhinolaryngol 274(3):1677–1681PubMed Selek A, Cetinarslan B, Tarkun I et al (2017) Thyroid autoimmunity: is really associated with papillary thyroid carcinoma? Eur Arch Otorhinolaryngol 274(3):1677–1681PubMed
23.
Zurück zum Zitat Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(7203):436–444PubMed Mantovani A, Allavena P, Sica A et al (2008) Cancer-related inflammation. Nature 454(7203):436–444PubMed
24.
Zurück zum Zitat Allavena P, Garlanda C, Borrello MG et al (2008) Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18(1):3–10PubMed Allavena P, Garlanda C, Borrello MG et al (2008) Pathways connecting inflammation and cancer. Curr Opin Genet Dev 18(1):3–10PubMed
26.
Zurück zum Zitat Guarino V, Castellone MD, Avilla E et al (2010) Thyroid cancer and inflammation. Mol Cell Endocrinol 321(1):94–102PubMed Guarino V, Castellone MD, Avilla E et al (2010) Thyroid cancer and inflammation. Mol Cell Endocrinol 321(1):94–102PubMed
27.
Zurück zum Zitat Larson SD, Jackson LN, Riall TS et al (2007) Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204(5):764–773 (discussion 73–5) PubMedPubMedCentral Larson SD, Jackson LN, Riall TS et al (2007) Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. J Am Coll Surg 204(5):764–773 (discussion 73–5) PubMedPubMedCentral
28.
Zurück zum Zitat Kang DY, Kim KH, Kim JM et al (2007) High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid 17(11):1031–1038PubMed Kang DY, Kim KH, Kim JM et al (2007) High prevalence of RET, RAS, and ERK expression in Hashimoto's thyroiditis and in papillary thyroid carcinoma in the Korean population. Thyroid 17(11):1031–1038PubMed
29.
Zurück zum Zitat Unger P, Ewart M, Wang BY et al (2003) Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? Hum Pathol 34(8):764–769PubMed Unger P, Ewart M, Wang BY et al (2003) Expression of p63 in papillary thyroid carcinoma and in Hashimoto's thyroiditis: a pathobiologic link? Hum Pathol 34(8):764–769PubMed
30.
Zurück zum Zitat Arif S, Blanes A, Diaz-Cano SJ (2002) Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41(4):357–362PubMed Arif S, Blanes A, Diaz-Cano SJ (2002) Hashimoto's thyroiditis shares features with early papillary thyroid carcinoma. Histopathology 41(4):357–362PubMed
31.
Zurück zum Zitat Vasileiadis I, Boutzios G, Charitoudis G et al (2014) Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol 21(8):2725–2732PubMed Vasileiadis I, Boutzios G, Charitoudis G et al (2014) Thyroglobulin antibodies could be a potential predictive marker for papillary thyroid carcinoma. Ann Surg Oncol 21(8):2725–2732PubMed
32.
Zurück zum Zitat Ahn D, Heo SJ, Park JH et al (2011) Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol 50(8):1228–1234PubMed Ahn D, Heo SJ, Park JH et al (2011) Clinical relationship between Hashimoto's thyroiditis and papillary thyroid cancer. Acta Oncol 50(8):1228–1234PubMed
33.
Zurück zum Zitat Song E, Oh HS, Jeon MJ et al (2019) The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma. Int J Cancer 144(6):1414–1420PubMed Song E, Oh HS, Jeon MJ et al (2019) The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma. Int J Cancer 144(6):1414–1420PubMed
34.
Zurück zum Zitat Kimura H, Yamashita S, Namba H et al (1992) Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab 75(2):596–602PubMed Kimura H, Yamashita S, Namba H et al (1992) Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab 75(2):596–602PubMed
35.
Zurück zum Zitat Cunha LL, Morari EC, Guihen AC et al (2012) Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 77(6):918–925 Cunha LL, Morari EC, Guihen AC et al (2012) Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf) 77(6):918–925
36.
Zurück zum Zitat Lucas SD, Karlsson-Parra A, Nilsson B et al (1996) Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 27(12):1329–1335PubMed Lucas SD, Karlsson-Parra A, Nilsson B et al (1996) Tumor-specific deposition of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 27(12):1329–1335PubMed
37.
Zurück zum Zitat Singh B, Shaha AR, Trivedi H et al (1999) Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 126(6):1070–1077PubMed Singh B, Shaha AR, Trivedi H et al (1999) Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. Surgery 126(6):1070–1077PubMed
38.
Zurück zum Zitat Rowe CW, Paul JW, Gedye C et al (2017) Targeting the TSH receptor in thyroid cancer. Endocr Relat Cancer 24(6):R191–R202PubMed Rowe CW, Paul JW, Gedye C et al (2017) Targeting the TSH receptor in thyroid cancer. Endocr Relat Cancer 24(6):R191–R202PubMed
39.
Zurück zum Zitat Boelaert K, Horacek J, Holder RL et al (2006) Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91(11):4295–4301PubMed Boelaert K, Horacek J, Holder RL et al (2006) Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 91(11):4295–4301PubMed
40.
Zurück zum Zitat Golbert L, de Cristo AP, Faccin CS et al (2017) Serum TSH levels as a predictor of malignancy in thyroid nodules: a prospective study. PLoS ONE 12(11):e0188123PubMedPubMedCentral Golbert L, de Cristo AP, Faccin CS et al (2017) Serum TSH levels as a predictor of malignancy in thyroid nodules: a prospective study. PLoS ONE 12(11):e0188123PubMedPubMedCentral
41.
Zurück zum Zitat Boi F, Minerba L, Lai ML et al (2013) Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest 36(5):313–320PubMed Boi F, Minerba L, Lai ML et al (2013) Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest 36(5):313–320PubMed
42.
Zurück zum Zitat Hegedus L, Hansen JM, Karstrup S (1983) High-incidence of normal thyroid-gland volume in patients with Graves-disease. Clin Endocrinol (Oxf) 19(5):603–607 Hegedus L, Hansen JM, Karstrup S (1983) High-incidence of normal thyroid-gland volume in patients with Graves-disease. Clin Endocrinol (Oxf) 19(5):603–607
43.
Zurück zum Zitat Beck-Peccoz P, Persani L, Mannavola D et al (2009) Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 23(5):597–606PubMed Beck-Peccoz P, Persani L, Mannavola D et al (2009) Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab 23(5):597–606PubMed
44.
Zurück zum Zitat Kim D, Park JW (2013) Clinical implications of preoperative thyrotropin serum concentrations in patients who underwent thyroidectomy for nonfunctioning nodule(s). J Korean Surg Soc 85(1):15–19PubMedPubMedCentral Kim D, Park JW (2013) Clinical implications of preoperative thyrotropin serum concentrations in patients who underwent thyroidectomy for nonfunctioning nodule(s). J Korean Surg Soc 85(1):15–19PubMedPubMedCentral
45.
Zurück zum Zitat Carayon P, Thomas-Morvan C, Castanas E et al (1980) Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 51(4):915–920PubMed Carayon P, Thomas-Morvan C, Castanas E et al (1980) Human thyroid cancer: membrane thyrotropin binding and adenylate cyclase activity. J Clin Endocrinol Metab 51(4):915–920PubMed
46.
Zurück zum Zitat Abe Y, Ichikawa Y, Muraki T et al (1981) Thyrotropin (TSH) receptor and adenylate cyclase activity in human thyroid tumors: absence of high affinity receptor and loss of TSH responsiveness in undifferentiated thyroid carcinoma. J Clin Endocrinol Metab 52(1):23–28PubMed Abe Y, Ichikawa Y, Muraki T et al (1981) Thyrotropin (TSH) receptor and adenylate cyclase activity in human thyroid tumors: absence of high affinity receptor and loss of TSH responsiveness in undifferentiated thyroid carcinoma. J Clin Endocrinol Metab 52(1):23–28PubMed
47.
Zurück zum Zitat McGriff NJ, Csako G, Gourgiotis L et al (2002) Effects of thyroid hormone suppression therapy on aciverse clinical outcomes in thyroia cancer. Ann Med 34(7–8):554–564PubMed McGriff NJ, Csako G, Gourgiotis L et al (2002) Effects of thyroid hormone suppression therapy on aciverse clinical outcomes in thyroia cancer. Ann Med 34(7–8):554–564PubMed
Metadaten
Titel
Anti-Thyroid Antibodies and TSH as Potential Markers of Thyroid Carcinoma and Aggressive Behavior in Patients with Indeterminate Fine-Needle Aspiration Cytology
verfasst von
Mohammadmehdi Adhami
Peter Michail
Apoorva Rao
Chhavi R. Bhatt
Simon Grodski
Jonathan W. Serpell
James C. Lee
Publikationsdatum
09.09.2019
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 2/2020
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-019-05153-1

Weitere Artikel der Ausgabe 2/2020

World Journal of Surgery 2/2020 Zur Ausgabe

Presidential Address

Mastery in Endocrine Surgery

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.